Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3: mevrometostat plus enzalutamide in metastatic castration-sensitive prostate cancer
2024-519369-24-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Mevrometostat + enzalutamide + ADT with Placebo + enzalutamide + ADT (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Jan 2026; status: authorised.
02
Drugs
mevrometostatenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-519369-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519369-24-00.